Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2026)

Denali Therapeutics has reported Non-Current Assets over the past 9 years, most recently at $244.2 million for Q4 2025.

  • Quarterly Non-Current Assets fell 52.09% to $244.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 54.25% year-over-year, with the annual reading at $244.2 million for FY2025, 52.09% down from the prior year.
  • Non-Current Assets was $244.2 million for Q4 2025 at Denali Therapeutics, up from $173.0 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $607.5 million in Q1 2024 and troughed at $81.7 million in Q2 2023.
  • The 5-year median for Non-Current Assets is $204.7 million (2022), against an average of $277.0 million.
  • Year-over-year, Non-Current Assets plummeted 82.66% in 2022 and then skyrocketed 621.67% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $506.9 million in 2021, then plummeted by 82.66% to $87.9 million in 2022, then grew by 2.11% to $89.8 million in 2023, then skyrocketed by 467.77% to $509.7 million in 2024, then plummeted by 52.09% to $244.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Non-Current Assets are $244.2 million (Q4 2025), $173.0 million (Q3 2025), and $231.5 million (Q2 2025).